189 related articles for article (PubMed ID: 25119501)
21. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
22. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
23. CRS + HIPEC combined with IP + IV chemotherapy for gastric signet-ring cell carcinoma: Case report of long-term survival.
Yan GJ; Ji ZH; Liu G; Li Y
Medicine (Baltimore); 2020 Oct; 99(41):e22647. PubMed ID: 33031325
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
Deng W; Wang QW; Zhang XT; Lu M; Li J; Li Y; Gong JF; Zhou J; Lu ZH; Shen L
World J Gastroenterol; 2014 Mar; 20(12):3356-63. PubMed ID: 24696615
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Bamias A; Karina M; Papakostas P; Kostopoulos I; Bobos M; Vourli G; Samantas E; Christodoulou Ch; Pentheroudakis G; Pectasides D; Dimopoulos MA; Fountzilas G
Cancer Chemother Pharmacol; 2010 May; 65(6):1009-21. PubMed ID: 20130877
[TBL] [Abstract][Full Text] [Related]
27. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
[TBL] [Abstract][Full Text] [Related]
28. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
29. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
30. Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Wei J; Costa C; Shen J; Yu L; Sanchez JJ; Qian X; Sun X; Zou Z; Gimenez-Capitan A; Yue G; Guan W; Rosell R; Liu B
Br J Cancer; 2014 May; 110(11):2662-8. PubMed ID: 24809779
[TBL] [Abstract][Full Text] [Related]
31. Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy.
Giampieri R; Baleani MG; Bittoni A; Rastelli F; Catalano V; Del Prete M; Chiorrini S; Pinterpe G; Graziano F; Giorgi FC; Bisonni R; Silva R; Alessandroni P; Mencarini L; Berardi R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444451
[TBL] [Abstract][Full Text] [Related]
32. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
[TBL] [Abstract][Full Text] [Related]
33. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
[TBL] [Abstract][Full Text] [Related]
35. Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy.
Li XT; Tang L; Chen Y; Li YL; Zhang XP; Sun YS
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1237-47. PubMed ID: 25537963
[TBL] [Abstract][Full Text] [Related]
36. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
Wei J; Costa C; Ding Y; Zou Z; Yu L; Sanchez JJ; Qian X; Chen H; Gimenez-Capitan A; Meng F; Moran T; Benlloch S; Taron M; Rosell R; Liu B
J Natl Cancer Inst; 2011 Oct; 103(20):1552-6. PubMed ID: 21862729
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
Richards D; McCollum D; Wilfong L; Sborov M; Boehm KA; Zhan F; Asmar L
Ann Oncol; 2008 Jan; 19(1):104-8. PubMed ID: 17897959
[TBL] [Abstract][Full Text] [Related]
38. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
[TBL] [Abstract][Full Text] [Related]
39. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Kanagavel D; Pokataev IA; Fedyanin MY; Tryakin AA; Bazin IS; Narimanov MN; Yakovleva ES; Garin AM; Tjulandin SA
Ann Oncol; 2010 Sep; 21(9):1779-1785. PubMed ID: 20150573
[TBL] [Abstract][Full Text] [Related]
40. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
